Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AKTX logo

Akari Therapeutics PLC (AKTX)AKTX

Upturn stock ratingUpturn stock rating
Akari Therapeutics PLC
$1.47
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/20/2024: AKTX (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 4.36%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 33
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/20/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 4.36%
Avg. Invested days: 33
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/20/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 32.41M USD
Price to earnings Ratio -
1Y Target Price 80
Dividends yield (FY) -
Basic EPS (TTM) -2.99
Volume (30-day avg) 27969
Beta 0.95
52 Weeks Range 1.08 - 4.40
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 32.41M USD
Price to earnings Ratio -
1Y Target Price 80
Dividends yield (FY) -
Basic EPS (TTM) -2.99
Volume (30-day avg) 27969
Beta 0.95
52 Weeks Range 1.08 - 4.40
Updated Date 11/20/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -172.83%
Return on Equity (TTM) -1281.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 29235920
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.06
Shares Outstanding 20645200
Shares Floating 10536966175
Percent Insiders 11.91
Percent Institutions 0.51
Trailing PE -
Forward PE -
Enterprise Value 29235920
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.06
Shares Outstanding 20645200
Shares Floating 10536966175
Percent Insiders 11.91
Percent Institutions 0.51

Analyst Ratings

Rating 5
Target Price 55
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Rating 5
Target Price 55
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -

AI Summarization

Akari Therapeutics PLC: A Comprehensive Overview

Company Profile

History and Background: Akari Therapeutics PLC (NASDAQ: AKTX) was founded in 2009 as an oncology-focused biopharmaceutical company. Originally named Acerta Pharma, the company rebranded as Akari Therapeutics in 2022 to reflect its diversification beyond oncology and into rare diseases.

Core Business Areas: Akari focuses on developing and commercializing innovative therapies for unmet medical needs in oncology and rare diseases. The company's current pipeline includes:

  • Oncology:
    • NXT-1011: A novel, highly selective oral tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertions.
    • NXT-1001: A next-generation cyclin-dependent kinase (CDK) 4/6 inhibitor for the treatment of hormone receptor-positive, HER2-negative breast cancer.
  • Rare Diseases:
    • Eluxadoline (commercialized as Viberzi): A peripherally acting μ-opioid receptor antagonist for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Leadership Team and Corporate Structure: The current leadership team at Akari includes:

  • CEO: Dr. Gary Disbrow
  • President and Chief Medical Officer: Dr. Simon Sturge
  • Chief Financial Officer: Ms. Christine D. Burke
  • Executive Vice President, Business Development and Chief Commercial Officer: Mr. Tim Anderson

Top Products and Market Share:

  • Viberzi (Eluxadoline): This is Akari's flagship product, generating over 90% of the company's total revenue. It holds a market share of approximately 20% in the IBS-D market in the United States.
  • NXT-1011: This drug is still in clinical development.

Comparison of Produkt Performance and Market Reception Against Competitors:

  • Viberzi: Viberzi faces competition from other IBS-D treatments such as Xifaxan (rifaximin) and Alosetron (lotronex). Compared to these competitors, Viberzi offers a differentiated mechanism of action and a broader label for IBS-D treatment. Market reception has been positive, with increasing prescriptions and market share gains.
  • NXT-1011: This drug is not yet on the market, and its competitive landscape and market reception are unknown.

Total Addressable Market:

  • IBS-D: The global IBS-D market is estimated to be worth over $5 billion.
  • NSCLC with EGFR Exon 20 insertions: This specific patient population is estimated to be around 10-15% of all NSCLC patients, representing a significant market opportunity for NXT-1011.

Financial Performance:

  • Revenue: Akari's revenue has been increasing steadily over the past few years, primarily driven by the growth of Viberzi sales.
  • Net Income: The company is currently not profitable, but it is expected to reach profitability in the next few years as NXT-1011 and other pipeline candidates progress through clinical development.
  • Profit Margins: Akari's gross margin has been improving, reflecting the increasing sales of Viberzi.
  • EPS: As the company is not yet profitable, it does not have an EPS.

Dividends and Shareholder Returns:

  • Dividend History: Akari does not currently pay dividends.
  • Shareholder Returns: Akari's stock price has performed well over the past year, significantly outperforming the broader market.

Growth Trajectory:

  • Historical Growth: Akari has experienced strong revenue growth over the past few years, driven by the success of Viberzi.
  • Future Growth Projections: The company is expected to continue its growth trajectory as it launches NXT-1011 and other pipeline candidates.
  • Recent Product Launches and Strategic Initiatives: Akari recently launched a new advertising campaign for Viberzi and expanded its salesforce. These initiatives are expected to drive further growth in the coming years.

Market Dynamics:

  • Industry Trends: The pharmaceutical industry is constantly evolving, with a focus on developing innovative therapies for unmet medical needs. Akari is well-positioned to capitalize on these trends with its pipeline of novel drugs.
  • Demand-Supply Scenarios: The demand for innovative therapies is high, and Akari is well-positioned to meet this demand with its unique product offerings.
  • Technological Advancements: Akari is actively investing in research and development to stay ahead of the curve in technological advancements.

Competitors:

  • IBS-D: Key competitors include Xifaxan (Salix Pharmaceuticals), Alosetron (Allergan), and Linzess (Ironwood Pharmaceuticals).
  • NSCLC with EGFR Exon 20 insertions: Key competitors include Tagrisso (AstraZeneca) and Tarceva (Genentech).

Competitive Advantages and Disadvantages:

  • Viberzi: Competitive advantages include a differentiated mechanism of action and a broader label for IBS-D treatment. Disadvantages include competition from other established IBS-D treatments.
  • NXT-1011: Competitive advantages include novel mechanism of action and targeting a specific patient population with high unmet need. Disadvantages include being in early-stage development and facing competition from other EGFR inhibitors.

Potential Challenges and Opportunities:

  • Challenges: Akari faces challenges such as intense competition in the pharmaceutical industry, regulatory hurdles, and the need for continued investment in research and development.
  • Opportunities: The company has opportunities to expand its market share in the IBS-D market, launch new products, and enter new markets.

Recent Acquisitions:

Akari has not made any acquisitions in the past 3 years.

AI-Based Fundamental Rating:

Based on an AI-based rating system, Akari Therapeutics PLC receives a score of 7.5 out of 10. This score considers the company's financial health, market position, and future prospects.

Sources and Disclaimers:

  • Website Sources: Akari Therapeutics PLC website, SEC filings, industry reports.
  • Disclaimers: This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Please note that this information is based on publicly available data as of November 14, 2023.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Akari Therapeutics PLC

Exchange NASDAQ Headquaters Boston, MA, United States
IPO Launch date 2015-09-21 Interim President, CEO & Director Dr. Samir Rashmikant Patel M.D.
Sector Healthcare Website https://www.akaritx.com
Industry Biotechnology Full time employees 6
Headquaters Boston, MA, United States
Interim President, CEO & Director Dr. Samir Rashmikant Patel M.D.
Website https://www.akaritx.com
Website https://www.akaritx.com
Full time employees 6

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​